Enanta Pharmaceuticals Inc（ENTA）财务数据ENTAEnanta Pharmaceuticals Inc

Evaluating the bottom line, Enanta Pharmaceuticals Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -120.04%, while the net margin is -135.81%. These profitability ratios, combined with a Return on Equity (ROE) of -70.12%, provide a clear picture of how effectively ENTA converts its operational activities into shareholder value.

In the context of the broader market, ENTA competes directly with industry leaders such as TKNO and CAPR. With a market capitalization of $339.02M, it holds a significant position in the sector. When comparing efficiency, ENTA's gross margin of 100.00% stands against TKNO's 37.73% and CAPR's N/A. Such benchmarking helps identify whether Enanta Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Enanta Pharmaceuticals reported total revenue of $14.36 million in Q3 2026, but it continues to show significant net losses, with a net income loss of $19.5 million. The gross margin remains strong at 100%, but the overall financial health is concerning due to the persistent losses.